← Therapy pipeline
Investigational · Obesity development

VK2735 oral

VK2735 · Viking Therapeutics

Once-daily oral GLP-1/GIP agonist; the Phase 3 SUNRISE program began in October 2026.

GLP-1GIP
Other study areas
Type 2 diabetesWeight maintenance / switching
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorViking Therapeutics
TargetsGLP-1 + GIP
RouteOral tablet
DevelopmentObesity-specific
01 / Evidence

Selected study results

VENTURE · tabletMean body-weight reductionBody weight decreased 12.2% · 13 weeks · Phase 2
Phase 2 · Oral · Sponsor-reported numerical results

Mean body-weight reduction · 13 weeks

Study focus: Weight management without type 2 diabetes

Investigational regimen
12.2%
Placebo / comparator
1.3%

Adults with obesity or overweight and a weight-related complication, without diabetes · 120 mg once daily after escalation vs placebo · Trial N=280 · Least-squares means; efficacy population; mixed model. Results & methods ↗

Only 7 weeks were spent at 120 mg. Oral and injectable milligram strengths are not equivalent.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIPTargeted
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

TabletOral tablet · Once daily
Phase 3SUNRISE-1 and SUNRISE-2 recruiting
Milestone → next

Latest: SUNRISE-1 and SUNRISE-2 are recruiting per November 16, 2026 registry postings, following Viking’s October 14 program-initiation announcement. Separate VENTURE oral Phase 2 results remain the current efficacy evidence.

Next: SUNRISE Phase 3 outcomes. The separate exploratory maintenance study began Part 2 in October 2026; it evaluates daily oral, monthly subcutaneous, or every-other-week subcutaneous maintenance after weekly injections, with results expected in 2027.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies2 records

Phase 3

SUNRISE-1

Weight management without type 2 diabetes
Study: RecruitingResults: Phase 3 results pending; registry recruiting as of November 16, 2026Status reviewed November 2026

Adults with obesity or overweight and a weight-related comorbidity, without type 2 diabetes; randomized, double-blind, placebo-controlled 68-week daily oral study. Estimated enrollment 560 in this protocol; primary endpoint is percent body-weight change at week 68. Recruiting per November 16 registry posting. The registry still labels the November 2026 start date as estimated; no Phase 3 results are posted.

Phase 3

SUNRISE-2

Weight management with type 2 diabetes
Study: RecruitingResults: Phase 3 results pending; registry recruiting as of November 16, 2026Status reviewed November 2026

Adults with obesity or overweight and a weight-related comorbidity, with type 2 diabetes; randomized, double-blind, placebo-controlled 68-week daily oral study. Estimated enrollment 560 in this protocol; primary endpoint is percent body-weight change at week 68. Recruiting per November 16 registry posting. The registry still labels the November 2026 start date as estimated; no Phase 3 results are posted.

Phase 2 studies1 record